



March 13, 2019

**Listing Department** 

**BSE LIMITED** 

P J Towers, Dalal Street, Fort,

Mumbai-400 001

**Listing Department** 

Code: CADILAHC

Code: 532 321

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex,

Bandra (E),

Mumbai-400 051

Re.: Press Release.

Dear Sir / Madam,

Please find enclosed a copy of press release dated March 13, 2019 titled "Zydus receives final approval from the USFDA for Potassium Chloride Extended-Release Capsules USP".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

AHMEDABAD

Thanking you,

Yours faithfully,

For, CADILA HEALTHCARE LIMITED

DHAVAL N. SONI COMPANY SECRETARY

Encl.: As above

Regd. Office: 'Zydus Tower', Satellite Cross Roads, Ahmedabad 380 015, India.

Phone: +91-79-2686 8100 (20 lines) www.zyduscadila.com CIN: L24230GJ1995PLC025878



Press Release

Press Release

## Zydus receives final approval from the USFDA for Potassium Chloride Extended-Release Capsules USP

Ahmedabad, 13 March 2019

Zydus Cadila has received the final approval from the USFDA to market Potassium Chloride Extended-Release Capsules USP (US RLD – Micro-K® Extended-Release Capsules), 8 mEq (600 mg) and 10 mEq (750 mg). It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

This medication is a mineral supplement used to treat or prevent low amounts of potassium in the blood. Potassium helps your cells, kidneys, heart, muscles and nerves work properly. Some conditions that can lower the body's potassium level include severe prolonged diarrhoea and vomiting, hormone problems such as hyperaldosteronism, or treatment with 'water pills'/diuretics.

The group now has 254 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.

## About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

\*\*\*

Phone: +91-79-2686 8100 (20 Lines) Fax: +91-79-2686 2365 www.zyduscadila.com

CIN: L24230GJ1995PLC025878